A treatment algorithm for autoimmune myasthenia gravis in childhood

Annals of the New York Academy of Sciences

Volumn 841, Issue , 1998, Pages 789-802

  Andrews, P Ian ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b SYDNEY CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CHOLINERGIC RECEPTOR ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HLA ANTIGEN; IMMUNOGLOBULIN; PREDNISOLONE; PYRIDOSTIGMINE; SEX HORMONE;

ABDOMINAL PAIN; ALGORITHM; AUTOIMMUNE DISEASE; CELLULAR IMMUNITY; CONFERENCE PAPER; DIARRHEA; EATON LAMBERT SYNDROME; ELECTROMYOGRAM; FLU LIKE SYNDROME; GROWTH RETARDATION; HEADACHE; HEART ATRIUM FIBRILLATION; HUMAN; HUMORAL IMMUNITY; HYPERTENSION; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNOMODULATION; INCIDENCE; INFERTILITY; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MUSCLE FATIGUE; MYASTHENIA GRAVIS; NAUSEA; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; PANCYTOPENIA; PLASMAPHERESIS; TERATOGENESIS; THYMECTOMY; VOMITING;

EID: 0031879903     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1998.tb11020.x     Document Type: Conference Paper

References (68)

1. ENGEL, A. G. 1984. Myasthenia gravis and myasthenic syndromes. Ann. Neurol. 16: 519-534.
2. DRACHMAN, D. B. 1994. Myasthenia gravis. N. Engl. J. Med. 330: 1797-1810.
3. LEWIS, R. A. et al. 1995. Myasthenia gravis: immunological mechanisms and immunotherapy. Ann. Neurol. 37(suppl. 1): S51-S62.
4. ANDREWS, P. I. et al. 1993. Acetylcholine receptor antibodies in juvenile myasthenia gravis. Neurology 43: 977-982.
5. MILLICHAP, J. G. & P. R. DODGE. 1960. Diagnosis and treatment of myasthenia gravis in infancy, childhood, and adolescence: a study of 51 patients. Neurology 10: 1007-1014.
6. SNEAD, O. C., III et al. 1980. Juvenile myasthenia gravis. Neurology 30: 732-739.
7. BATOCCHI, A. P. et al. 1990. Early-onset myasthenia gravis: clinical characteristics and response to therapy. Eur. J. Pediatr. 150: 66-68.
8. ANDREWS, P. J. et al. 1994. Race, sex, and puberty influence onset, severity, and outcome in juvenile myasthenia gravis. Neurology 44: 1208-1214.
9. MATSUKI, K. et al. 1990. HLA antigens in Japanese patients with myasthenia gravis. J. Clin. Invest. 86: 392-399.
10. PHILLIPS, L. H., II et al. 1992. The epidemiology of myasthenia gravis in central and western Virginia. Neurology 42: 1888-1893.
11. CHIU, H-C. et al. 1987. Myasthenia gravis: population differences in disease expression and acetylcholine receptor antibody titers between Chinese and Caucasians. Neurology 37: 1854-1857.
12. UONO, M. 1980. Clinical statistics of myasthenia gravis in Japan. Int. J. Neurol. 14: 87-99.
13. DEPARTMENT OF HUMAN RESOURCES, DIVISION OF HEALTH SERVICES, OFFICE OF MANAGEMENT, NORTH CAROLINA VITAL STATISTICS. 1980. 1979, Vol. 1: births, deaths, population, marriages, divorces.
14. SPRENT, J. 1993. T lymphocytes and the thymus. In Fundamental Immunology. Third edition, pp. 75-109. Raven Press. New York.
15. LAWTON, A. R. & M. D. COOPER. 1989. Ontogeny of immunity. In Immunologic Disorders in Infants and Children. Third edition, pp. 1-14. Saunders. Philadelphia.
16. GROSSMAN, C. J. 1984. Regulation of the immune system by sex steroids. Endocr. Rev. 5: 435-455.
17. FURUKAWA, F. et al. 1988. Estradiol enhances binding to cultured human keratinocytes of antibodies specific for SS-A/RO and SS-B/LA: another possible mechanism for estradiol influence of lupus erythematosus. J. Immunol. 141: 1480-1488.
18. VON GAUDECKER, B. 1991. Functional history of the human thymus. Anat. Embryol. 183: 1-15.
19. PAAVONEN, T. 1994. Hormonal regulation of immune responses. Ann. Med. 26: 255-258.
20. ELSASSER-BEILE, U. et al. 1995. Comparison of cytokine production in blood cell cultures of healthy children and adults. Pediatr. Asthma Allergy Immunol. 6(3): 170-174.
21. SEYBOLD, M. E. et al. 1971. Thymectomy in juvenile myasthenia gravis. Arch. Neurol. 25: 385-392.
22. RODRIGUEZ, M. et al. 1983. Myasthenia gravis in children: long-term follow-up. Ann. Neurol. 13: 504-510.
23. VINCENT, A. et al. 1993. Seronegative myasthenia gravis: evidence for plasma factor(s) interfering with acetylcholine receptor function. Ann. N.Y. Acad. Sci. 681: 529-538.
24. KEYNES, G. 1954. Surgery of the thymus gland: second (and third) thoughts. Lancet 1: 1197-1202.
25. SIMPSON, J. A. 1958. An evaluation of thymectomy in myasthenia gravis. Brain 81: 112-114.
26. SHIBUYA, N. et al. 1994. Immunoadsorption therapy for myasthenia gravis. J. Neurol. Neurosurg. Psychiatry 57: 578-581.
27. ADAMS, C. et al. 1990. Thymectomy in juvenile myasthenia gravis. J. Child Neurol. 5: 215-218.
28. FURUSHO, K. et al. 1984. High-dose intravenous gamma globulin for Kawasaki disease. Lancet 2: 1055-1058.
29. GAJDOS, P. 1994. Intravenous immune globulin in myasthenia gravis. Clin. Exp. Immunol. 97(suppl.): 49-51.
30. EVOLI, A. et al. 1993. High-dose intravenous immunoglobulin in myasthenia gravis. Ital. J. Neurol. Sci. 14: 233-237.
31. EDAN, G. & F. LANDGRAF. 1994. Experience with intravenous immunoglobulin in myasthenia gravis. J. Neurol. Neurosurg. Psychiatry 57(suppl.): 55-56.
32. KLASSEN, T. P. et al. 1993. Economic evaluation of intravenous immune globulin therapy for Kawasaki syndrome. J. Pediatr. 122: 538-542.
33. NEWBURGER, J. W. et al. 1986. The treatment of Kawasaki syndrome with intravenous gamma globulin. N. Engl. J. Med. 315: 341-347.
34. STRICKER, R. B. et al. 1993. Myasthenia crisis: response to plasmapheresis following failure of intravenous gamma globulin. Arch. Neurol. 50: 837-840.
35. BRANNAGAN, T. H., III et al. 1996. Complications of intravenous immune globulin treatment in neurologic disease. Neurology 47: 674-677.
36. FASANO, M. B. 1995. Risks and benefits of intravenous immunoglobulin treatment in children. Curr. Opin. Pediatr. 7: 688-694.
37. BUNDEY, S. 1972. A genetic study of infantile and juvenile myasthenia gravis. J. Neurol. Neurosurg. Psychiatry 35: 41-51.
38. CAMPBELL, J. R. et al. 1983. Surgical treatment of myasthenia gravis in childhood. J. Pediatr. Surg. 18: 857-861.
39. HANSSON, O. et al. 1972. Thymectomy in juvenile myasthenia gravis. Neuropaediatrie 3: 429-463.
40. RYNIEWICZ, B. & B. BADURSKA. 1977. Follow-up study of myasthenic children after thymectomy. J. Neurol. 217: 133-138.
41. SARNAT, H. B. et al. 1977. Effective treatment of infantile myasthenia gravis by combined prednisone and thymectomy. Neurology 27: 550-553.
42. YOUSSEF, S. 1983. Thymectomy for myasthenia gravis in children. J. Pediatr. Surg. 18: 537-541.
43. MASAOKA, A. et al. 1996. Extended thymectomy for myasthenia gravis patients: a 20-year review. Ann. Thorac. Surg. 62: 853-859.
44. NAKAMURA, H. et al. 1996. Delayed remission after thymectomy for myasthenia gravis of the purely ocular type. J. Thorac. Cardiovasc. Surg. 112: 371-375.
45. MILLER, J. & D. OSOBA. 1967. Current concepts of the immunological function of the thymus. Physiol. Rev. 47: 437-520.
46. BREARLEY, S. et al. 1987. Immunodeficiency following neonatal thymectomy in man. Clin. Exp. Immunol. 70: 322-327.
47. PAPATESTAS, A. E. et al. 1972. Ketosteroid excretion, myasthenia gravis, and breast cancer. Lancet 1: 691-692.
48. VESSEY, M. P. & R. DOLL. 1972. Thymectomy and cancer - a follow-up study. Br. J. Cancer 26: 53-58.
49. TANNER, J. M. & P. S. W. DAVIES. 1985. Clinical longitudinal standards for height and height velocity for North American children. J. Pediatr. 107: 317-329.
50. OLAKOW, C. W. et al. 1987. Thymectomy as primary therapy in myasthenia gravis. Ann. N.Y. Acad. Sci. 505: 595-606.
51. PASCUZZI, R. M. et al. 1984. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann. Neurol. 15: 291-298.
52. KUPERSMITH, M. J. et al. 1996. Beneficial effects of corticosteroids on ocular myasthenia gravis. Arch. Neurol. 53: 802-804.
53. BADURSKA, B. et al. 1992. Immunosuppressive treatment for juvenile myasthenia gravis. Eur. J. Pediatr. 151: 215-217.
54. LINDBERG, C. et al. 1992. Remission rate after thymectomy in myasthenia gravis when the bias of immunosuppressive therapy is eliminated. Acta Neurol. Scand. 86: 323-328.
55. KERRIBIJN, K. F. & J. P. M. DE KROON. 1968. Effect on height of corticosteroid therapy in asthmatic children. Arch. Dis. Child. 43: 556-561.
56. REES, L. et al. 1988. Growth and endocrine function in steroid sensitive nephrotic syndrome. Arch. Dis. Child. 63: 484-490.
57. LETTGEN, B. et al. 1994. Influence of steroid medication on bone mineral density in children with nephrotic syndrome. Pediatr. Nephrol. 8: 667-670.
58. ARSURA, E. et al. 1985. High-dose intravenous methylprednisolone in myasthenia gravis. Arch. Neurol. 42: 1149-1153.
59. SAKANO, T. et al. 1989. Treatment for refractory myasthenia gravis. Arch. Dis. Child. 64: 1191-1193.
60. TANAKA, J. et al. 1994. Intermittent methylprednisolone pulse therapy for myasthenia gravis in childhood. Brain Dev. 26: 14-19.
61. BOCANEGRA, T. S. et al. 1981. Sudden death after methylprednisolone pulse therapy. Ann. Intern. Med. 95: 122.
62. MCLUCKIE, A. E. & R. W. SAVAGE. 1993. Atrial fibrillation following pulse methylprednisolone therapy in an adult. Chest 104: 622-623.
63. PANEGYRES, P. K. et al. 1993. Acute myopathy associated with large parenteral dose of corticosteroid in myasthenia gravis. J. Neurol. Neurosurg. Psychiatry 56: 702-704.
64. COSL, V. et al. 1992. Azathioprine as a single immunosuppressive drug in the treatment of myasthenia gravis. Acta Neurol. 15: 123-131.
65. CONFAVREUX, C. et al. 1996. Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology 46: 1607-1612.
66. TINDALL, R. S. A. et al. 1993. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann. N.Y. Acad. Sci. 681: 539-551.
67. PEREZ, M. C. et al. 1981. Stable remissions in myasthenia gravis. Neurology 31: 32-37.
68. NAIKAN, E. et al. 1986. Immunosuppressive drug therapy in myasthenia gravis. Arch. Neurol. 43: 155-156.